Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Cardinal Infrastructure raises cash portion of Hughes Brothers acquisition to 60%

Cardinal Infrastructure raises cash portion of Hughes Brothers acquisition to 60%

BitgetBitget2026/10/19 11:31
  • Cardinal Infrastructure Group amended its $357.5 million Hughes Brothers Construction acquisition to 60% cash and 40% stock, from 50% each.
  • Sellers will receive approximately $214.5 million cash and 5,255,420 Class A common shares at an issue price of $27.21 per share.
  • The revised earnout offers up to $162.5 million based on Hughes Brothers’ adjusted EBITDA for the 12 months ending June 30, 2027.
  • Earnout payments will comprise 60% cash and 40% stock, including up to approximately 2,388,827 additional shares at $27.21 each.
  • Closing remains expected in the fourth quarter of 2026, with cash consideration funded through cash on hand and existing credit facility borrowings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardinal Infrastructure Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610190730PR_NEWS_USPR_____CL74951) on October 19, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12